Navigation Links
Persistent Vaccination Effect of GRAZAX(R) After Completion of Treatment
Date:10/22/2008

COPENHAGEN, October 22 /PRNewswire-FirstCall/ -- Breakthrough: Results from the fourth year in a long-term clinical study prove the disease modifying effect of GRAZAX(R). For the first time ever, it is documented that the positive clinical effect of the tablet vaccine persists after completion of treatment.

Today, ALK announces main results from the first follow-up year in a long-term study (GT-08) with GRAZAX(R), the company's tablet-based vaccine against grass pollen allergy. The clinical study documents that the effect of GRAZAX(R) persists following completion of the recommended three-year treatment regimen. Furthermore, blood samples from patients show a persistent, positive effect on the immune system indicating a lasting tolerance to grass pollen.

During the first year after completion of treatment, GRAZAX(R) continues to provide statistically significant reductions in both hay fever symptoms and the use of symptom-relieving medication.

In the follow-up year, hay fever symptoms were reduced by 31% while the use of symptom-relieving medication was reduced by 52%. The reduction of symptoms and use of medication is measured as median values relative to a control group in which patients had unrestricted access to symptom-relieving medication.

The patients in the study have adhered to the recommended three-year GRAZAX(R) treatment regimen and completed treatment in the autumn of 2007. The above-mentioned results cover the 2008 pollen season, the first season in which the patients did not receive active treatment with GRAZAX(R).

The fourth-year results represent a major breakthrough, since ALK is the first company ever to document a persistent disease modifying vaccination effect of a tablet-based allergy vaccine. Patients cannot obtain such a persistent vaccination effect with traditional symptom-relieving allergy medication.
ALK-Abelló A/S - Company release No 14/2008 - October 22, 2008

ALK-Abelló A/S

Jens Bager

President and CEO

For further information please contact:

Jens Bager, President and CEO, tel. +45-4575-7576

Investor Relations: Per Plotnikof, tel +45-4574-7527, mobile +45-2261-2525

Press: Jacob Frische, tel +45-4574-7551, mobile +45-2224-7551


'/>"/>
SOURCE ALK-Abello A/S
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
2. Phase III Trial Finds Pharmaxis Bronchitol Effective
3. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
4. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
5. New nanoparticle vaccine is more effective but less expensive
6. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
7. ProMed Alliance International Inc. Corporate Name and Trading Symbol Expected to Change Effective Tomorrow
8. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
9. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
10. Job-related stress: NIST demonstrates fatigue effects in silicon
11. Free White Paper Available for Clinical Laboratory Managers: Effectively Isolating Anaerobic Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... Alto, CA, USA (PRWEB) , ... April 26, ... ... popular seminar on FDA’s GMP expectations for phase I clinical trials comes to ... attended by various biotechnology and pharma professionals representing FDA regulated organizations such as ...
(Date:4/26/2017)... , April 26, 2017  Genisphere LLC, ... platform, has signed a collaborative and sponsored research ... Silvia Muro . The overall goal of ... pharmacodynamics of various 3DNA designs and formulations after ... targeting diseases of the vasculature as well as ...
(Date:4/25/2017)... ... 25, 2017 , ... Dr. Robert G. Schwartz, the principal ... today that acclaimed physiatrist Matthew Terzella, MD, has joined the practice as a ... Terzella completed his residency in Physical Medicine and Rehabilitation at UMDNJ-Robert Wood Johnson ...
(Date:4/21/2017)... DENVER, COLORADO (PRWEB) , ... April 21, 2017 ... ... Manufacturing. Awards recognized outstanding manufactures in 10 categories with over 30 nominees and ... Women in Manufacturing presented the new award and the event was hosted by ...
Breaking Biology Technology:
(Date:3/22/2017)... Lithuania , March 21, 2017   ... and object recognition technologies, today announced the release ... kit (SDK), which provides improved facial recognition using ... cameras on a single computer. The new version ... to improve accuracy, and it utilizes a Graphing ...
(Date:3/22/2017)... Calif. , March 21, 2017 ... analytics company serving law enforcement agencies, announced today the ... as director of public safety business development. ... diversified law enforcement experience, including a focus on the ... In his most recent position, Mr. Sheridan served as ...
(Date:3/20/2017)... 20, 2017 PMD Healthcare announces the release ... Wellness Management System (WMS), a remote, real-time lung health ... PMD Healthcare is a Medical Device, Digital Health, and ... to creating innovative solutions that empower people to improve ... focus, PMD developed the first ever personal spirometer, Spiro ...
Breaking Biology News(10 mins):